Effect of the α-glucosidase inhibitor acarbose on control of glycemia in dogs with naturally acquired diabetes mellitus
Authors:
- Jane RobertsonJRJane Robertson
- Edward C. FeldmanEFEdward C. Feldman
- Carolyn BriggsCBCarolyn Briggs
- 15 April 2000
- journal article
- clinical trial
- Published by American Veterinary Medical Association (AVMA) in Journal of the American Veterinary Medical Association
- Vol. 216 (8) , 1265-1269
Abstract
Objective—To evaluate effect of acarbose on control of glycemia in dogs with diabetes mellitus. Design—Prospective randomized crossover controlled trial. Animals—5 dogs with naturally acquired diabetes mellitus. Procedure—Dogs were treated with acarbose and placebo for 2 months each: in 1 of 2 randomly assigned treatment sequences. Dogs that weighed ≤ 10 kg (22 lb; n = 3) or > 10 kg (2) were given 25 or 50 mg of acarbose, respectively, at each meal for 2 weeks, then 50 or 100 mg of acarbose, respectively, at each meal for 6 weeks, with a 1-month interval between treatments. Caloric intake, type of insulin, and frequency of insulin administration were kept constant, and insulin dosage was adjusted as needed to maintain control of glycemia. Serum glucose concentrations, blood glycosylated hemoglobin concentration, and serum fructosamine concentration were determined. Results—Significant differences in mean body weight and daily insulin dosage among dogs treated with acarbose and placebo were not found. Mean preprandial serum glucose concentration, 8-hour mean serum glucose concentration, and blood glycosylated hemoglobin concentration were significantly lower in dogs treated with insulin and acarbose, compared with insulin and placebo. Semisoft to watery feces developed in 3 dogs treated with acarbose. Conclusions and Clinical Relevance—Acarbose may be useful as an adjunctive treatment in diabetic dogs in which cause for poor glycemic control cannot be identified, and insulin treatment alone is ineffective. (J Am Vet Med Assoc 2000;216:1265–1269)Keywords
This publication has 22 references indexed in Scilit:
- A Risk-Benefit Appraisal of Acarbose in the Management of Non-Insulin-Dependent Diabetes MellitusDrug Safety, 1994
- Acarbose and insulin therapy in type I diabetes mellitusEuropean Journal of Clinical Investigation, 1994
- AcarboseDrugs, 1993
- Low-Dose Acarbose Improves Glycemic Control in NIDDM Patients Without Changes in Insulin SensitivityDiabetes Care, 1993
- Oral Antidiabetic AgentsDrugs, 1992
- Nutritional Recommendations for Diabetic Patients and Treatment with α-Glucosidase InhibitorsDrugs, 1992
- Safety Profile of Acarbose, an α-Glucosidase InhibitorDrugs, 1992
- AcarboseDrugs, 1988
- The effects of theα-glucosidase inhibitor BAY g 5421 (Acarbose) on postprandial blood glucose, serum insulin, and triglyceride levels: Dose-time-response relationships in manZeitschrift für Die Gesamte Experimentelle Medizin, 1979
- The effects of theα-glucosidase inhibitor BAY g 5421 (Acarbose) on meal-stimulated elevations of circulating glucose, insulin, and triglyceride levels in manZeitschrift für Die Gesamte Experimentelle Medizin, 1979